36 results about "Serum iron tests" patented technology

Modulation of iron homeostasis by regulating BMP-6 activity is provided. Methods of using BMP-6 and BMP-6 protein-specific reagents, such as antibodies, for altering serum iron levels in humans are provided. Such antibodies are useful in pharmaceutical compositions for the prevention and treatment of hemochromatosis and anemia of inflammation.

The invention discloses an RNA with little interference for inhibiting the expression of an iron regulating element regulatory protein (HJV). The RNA with little interference is in reverse complementation with the iron regulating element regulatory protein gene mRNA, and the length of the RNA is 19-27bp. The invention further discloses a DNA for coding the corresponding shRNA of the RNA with little interference and a recombined slow virus capable of expressing the shRNA. The RNA with little interference, the DNA capable of coding the shRNA and the recombined slow virus can effectively inhibit the expression of the iron regulating element regulatory protein in vivo, improve the level of the iron regulating element and reduce the level of serum iron in vivo, thereby reaching the aim of curing diseases related to iron metabolism.

Modulation of iron homeostasis by regulating BMP-6 activity is provided. Methods of using BMP-6 and BMP-6 protein-specific reagents, such as antibodies, for altering serum iron levels in humans are provided. Such antibodies are useful in pharmaceutical compositions for the prevention and treatment of hemochromatosis and anemia of inflammation.

Modulation of iron homeostasis by regulating BMP-6 activity is provided. Methods of using BMP-6 and BMP-6 protein-specific reagents, such as antibodies, for altering serum iron levels in humans are provided. Such antibodies are useful in pharmaceutical compositions for the prevention and treatment of anemia and anemia of inflammation.

The invention belongs to the field of radiation biological dose meters, and particularly relates to a characteristic project estimation technique using serum iron and serum copper as a marker. The technique includes the steps of measuring the concentration of the serum iron and the concentration of the serum copper of a radiated mouse respectively by using a 2-(5-bromine-2-pyridine azobenzene)-5-2-diethylaminophenol (5-Br-PADAP) spectrophotometric method, calculating the ratio of the serum iron and the serum copper, and then establishing a dose-response curve between the serum iron / serum copper and a radiation dose. According to the established dose-response curve, the dose response range of the biological dose estimation technique is 0.5-7Gy, operation and index analysis are convenient, information of the radiation dose can be acquired in 30 minutes, and the requirement for biological dose reconstruction can be met. Due to the fact that the technique has the advantages that the dose response is good, detection is convenient and mass detection can be carried out, the technique has broad application prospects in biological dose estimation for nuclear radiation accidents or professional radiated workers.

The invention belongs to the fields of medicines and pharmacology, and relates to a novel pharmaceutical application of hydrogen sulfide in pharmacology, in particular to an application of the hydrogen sulfide in preparing medicines for treating inflammatory anemia. By conducting experiments on the influence of the hydrogen sulfide on the serum iron of normal mice and mice with the inflammatory anemia, experimental results indicate that the hydrogen sulfide, under a physiological condition, can significantly improve the serum iron and iron-carrying saturation of the mice by increasing TFR (transferrin receptor) protein expression; for a model of the mice with the inflammatory anemia, the hydrogen sulfide, by inhibiting the decrease of TFR and EPN proteins caused by lipopolysaccharide, can significantly inhibit the decline of the serum iron and iron-carrying saturation caused by the lipopolysaccharide; and for peritoneal induced primary macrophage, the hydrogen sulfide, under the physiological condition, can significantly increase the TFR protein expression, and for a lipopolysaccharide-processed cell mode, the hydrogen sulfide can inhibit lipopolysaccharide-induced TFR decrease. The experimental results prove that the hydrogen sulfide can be used for preparing the medicines for treating the inflammatory anemia.

The invention discloses a serum iron determination kit. The kit comprises a reagent R1 and a reagent R2. The reagent R1 comprises a buffer solution, ascorbic acid, a de-interfering agent, a stabilizer, a surfactant, and a preservative. The reagent R2 comprises a buffer solution and bathophenanthroline disulfonic acid disodium salt. The invention further relates to a preparation method and application of the serum iron determination kit. The stable serum iron is a liquid double-reagent, reconstitution preparation is not required, and therefore the stable serum iron can be directly used when taken out from a bottle. The stabilizer is added in the reagent R1 to facilitate stability and reducibility maintenance of the ascorbic acid. The de-interfering agent is added in the reagent R1, thioureais mixed with a ascorbic acid solution, and therefore the R1 can be adopted as a masking agent as well as a reducing agent, and interference from other ions can be avoided. The reagent has high sensitivity. The kit is convenient to use, is high in specificity, is high in accuracy, is free of pollution to biochemical instruments, and can be further popularized in the market.

Disclosed herein are compounds, compositions and methods for modulating the expression of hepcidin in a cell, tissue or animal or preventing, ameliorating or treating anemia. Also provided are methods for prevention, amelioration or treatment of anemia, and for increasing red blood cell count in an animal. Also provided are methods for the prevention, amelioration and / or treatment of low serum iron levels, low red blood cell count and other clinical endpoints of anemia in an animal. These methods may be achieved by administration of compounds or compositions including antisense compounds targeted to a nucleic acid that expresses hepcidin polypeptide combined with an erythropoiesis stimulating agent.

The invention discloses a thiazolidone compound, wherein a chemical structure of the thiazolidone compound is shown in a general form (I). The invention also discloses application of the thiazolidone compound in preparation of a medicine used for treating thalassemia. Experiments prove that the thiazolidone compound can be used for effectively stimulating expression of hepcidin in cells under the condition that concentration is 10mu M, can be still used for effectively inducing expression of hepcidin in liver when being exposed for 6 hours, 24 hours and 48 hours respectively at a dosage of 30mg / kg in animal level and can be also used for effectively reducing level of serum iron, so that the thiazolidone compound can take hepcidin as a target, can be used for reducing iron level in serum, is hopeful to be a potential medicine used for treating and alleviating iron disorder-related diseases and has a broad clinical application prospect and a great economic development value.

The invention discloses a kit for measuring serum iron. The kit contains reagent R1 and reagent R2; the reagent R1 is composed of buffer, ascorbic acid, interference removing agent, stabilizer, surfactant and preservative; the reagent R2 The invention contains the following components: a buffer solution and saphenanthroline; and also relates to a preparation method and application of a kit for measuring serum iron. The stable serum iron of the present invention is a liquid double reagent, which does not need to be redissolved for preparation, and can be used directly after opening the bottle. By adding a stabilizer to the reagent R1, it is beneficial to maintain the stability and reducibility of ascorbic acid. Reagent R1 is added with interference removing agent, and thiourea is mixed with ascorbic acid solution, which can be used as reducing agent and masking agent to remove the interference of other ions. This reagent has higher sensitivity. The reagent is convenient to use, has high specificity, high accuracy, and has no pollution to biochemical instruments, which is conducive to the further promotion of the reagent in the market.

The invention belongs to the technical field of pharmaceutical extraction and discloses a preparation method of a pharmaceutical preparation used for iron-deficiency anemia. The preparation method comprises the following steps: 1) preparing a porphyra extract; 2) preparing agaric extracting solution; 3) preparing a fructus lycii extract; 4) preparing a Chinese date extract; 5) preparing peanut skin extracting solution; and 6) boiling, filtering, subpackaging and sterilizing. The pharmaceutical preparation can obviously improve contents of red blood cells, hemoglobin and serum iron, has the effect obviously better than that of the prior art and can be further applied to clinical experimental study.

The invention discloses a medicine application of iron liposome. By taking animals with chronic inflammation as a model, a brand-new medicine which treats anaemia caused by the dysfunction of the iron absorption of the small intestine to relevant protein molecules and takes the iron liposome as an effective component is provided. The invention takes white rats with inflammatory anaemia as a model, adopts an oral stomach infusion method and compares the curative effect of the iron liposome for the anaemia with that of a chalybeate which is not enveloped by the liposome, and the iron liposome can obviously enhance the levels of the hemoglobin, the blood cell volume, the serum iron and the saturation rate of the transferrin of an organism in a short time, can act as a very good curative effect to the inflammatory anaemia and can not cause injuries to the health of the organism. The iron liposome is obviously superior to the traditional iron-replenished preparation. The invention can be used for treating the anaemia caused by the dysfunction of the iron absorption of the small intestine to the protein molecules because of various known or unknown reasons. Various tablets, capsules, dripping pills, oral liquid and food additives which are taken orally and contain the iron liposome are prepared.